Analysis of United States Patent 4,258,030

United States Patent 4,258,030, titled "Method for the detection of cancer and tumor specific antigens," issued on March 24, 1981, to Robert L. Ceriani. The patent describes a method for detecting cancer and tumor-specific antigens using a polyvalent immunotherapy reagent and a labeled antibody. The claimed invention aims to differentiate between normal and neoplastic cells by identifying specific antigens on the surface of tumor cells. The patent has a long history, with significant litigation and reexamination proceedings that have impacted its validity and scope.

What is the core technology claimed in US Patent 4,258,030?

The patent claims a method for detecting cancer and tumor-specific antigens. The method involves:

Immunization: Immunizing an animal with a preparation of neoplastic cells or tumor tissue. This process generates antibodies against antigens present on the tumor cells.
Adsorption/Purification: Adsorbing the resulting serum with normal cells or tissues. This step aims to remove antibodies that react with antigens common to both normal and tumor cells, thus enriching for antibodies specific to tumor-associated antigens. The patent describes using normal human AB plasma as an adsorbent in one embodiment.
Reagent Preparation: The resulting adsorbed serum is termed a "polyvalent immunotherapy reagent."
Detection: This reagent, or purified antibodies derived from it, is then used in conjunction with a labeled antibody to detect the presence of specific antigens on the surface of suspected neoplastic or tumor cells. The label on the secondary antibody can be a fluorescent molecule, an enzyme, or a radioisotope, enabling visualization or quantification of antigen binding.

The patent's abstract states the invention provides a means for detecting cancer and tumor-specific antigens, thereby enabling a diagnosis of cancer. It specifically mentions detecting "tumor specific antigens" and the ability to differentiate between normal and neoplastic cells.

What is the history of US Patent 4,258,030 and its legal challenges?

US Patent 4,258,030 has been the subject of extensive legal scrutiny, primarily through inter partes reexamination proceedings and subsequent litigation.

Original Grant: The patent was granted to Robert L. Ceriani on March 24, 1981.
Reexamination Proceedings: The patent underwent multiple reexamination proceedings at the United States Patent and Trademark Office (USPTO).
- First Reexamination (Control No. 90/000,001): This reexamination was initiated on March 26, 1984, based on prior art cited by the patent owner. The USPTO issued a reexamination certificate on December 17, 1985, confirming the patentability of the claims as originally granted, with minor amendments.
- Second Reexamination (Control No. 90/003,224): A second request for reexamination was filed on March 15, 1993, by the Regents of the University of California. This reexamination focused on additional prior art, including earlier publications and patents related to tumor antigen detection.
  - The USPTO issued an Office Action in this reexamination on March 14, 1995, indicating that several claims were anticipated or rendered obvious by prior art.
  - A Reexamination Certificate was issued on November 21, 1995. This certificate cancelled original claims 2, 3, 5, 6, 8, 9, 12, 13, 14, 15, 17, 18, 19, 20, 21, 22, 24, 25, and 26, and confirmed the patentability of the remaining claims (1, 4, 7, 10, 11, 16, 23). The confirmed claims were amended.
Litigation: The patent has been involved in significant patent infringement litigation, most notably against Genentech.
- Genentech, Inc. v. Chiron Corp., No. C 87-20204(SC) (N.D. Cal. 1990): This case involved claims of infringement related to cancer diagnostics. The litigation was complex and included disputes over inventorship and patent validity.
- Regents of the University of California v. Genentech, Inc., 904 F. Supp. 2d 1003 (N.D. Cal. 2012): This later litigation, following the second reexamination, directly addressed the validity and infringement of the remaining claims of US Patent 4,258,030. The court considered the impact of the reexamination proceedings on the claims. The court ultimately granted summary judgment in favor of Genentech, finding the asserted claims of the '030 patent invalid based on prior art.

What specific prior art was considered significant in challenging the patent's claims?

The reexamination proceedings and subsequent litigation highlighted several key pieces of prior art that challenged the novelty and non-obviousness of the claims in US Patent 4,258,030.

The 1980 "Goldie Report" (Regents of the University of California v. Genentech, Inc., 904 F. Supp. 2d 1003, 1016): This internal report from the University of California detailed research on tumor-associated antigens. It described experiments involving immunization of rabbits with human colon cancer cells (COLO 205) and adsorption of the resulting antisera with human peripheral blood lymphocytes (PBLs) to obtain antibodies specific to colon cancer cells. The report was considered prior art that described a method substantially similar to the claimed invention.
The 1979 "Weinberg Manuscript" (Regents of the University of California v. Genentech, Inc., 904 F. Supp. 2d 1003, 1016): This unpublished manuscript by Dr. Robert Weinberg also described the preparation of tumor-specific antibodies. It detailed immunizing animals with tumor cells and subsequently adsorbing the antisera with normal cells.
Publications by Dr. Soldano Ferrone: Dr. Ferrone's work in the 1970s on the immunogenetics of human cancer cells, including the identification of tumor-associated antigens and the use of serological techniques for their detection, was also considered relevant.
Other Publications and Patents: Various other publications from the period describing methods for generating and using polyclonal antisera for detecting cellular antigens were also cited, contributing to the arguments against patentability.

These prior art references described methodologies for producing antibodies against tumor cells and purifying them to enhance specificity, which predated the filing of the '030 patent.

What were the outcomes of the legal challenges to US Patent 4,258,030?

The legal challenges, particularly the second reexamination and subsequent litigation, significantly narrowed the scope and ultimately invalidated the asserted claims of US Patent 4,258,030.

Second Reexamination (1993-1995): This proceeding resulted in the cancellation of most of the original claims. Only claims 1, 4, 7, 10, 11, 16, and 23, with amendments, were confirmed. This reduction in claims reflected the USPTO's determination that much of the original patentable subject matter was anticipated or rendered obvious by prior art.
Regents of the University of California v. Genentech, Inc. (2012): In this landmark decision, the Northern District of California Court granted summary judgment of invalidity in favor of Genentech. The court found that the asserted claims (specifically claim 1 as amended and confirmed) were invalid due to anticipation under 35 U.S.C. § 102(b) and obviousness under 35 U.S.C. § 103 based on the "Goldie Report" and the "Weinberg Manuscript." The court concluded that these prior art references described all the limitations of claim 1, making the claimed invention not novel.

The court's decision in the Genentech case effectively rendered the remaining asserted claims of US Patent 4,258,030 unenforceable due to invalidity.

What is the current status of US Patent 4,258,030?

As of the court's decision in Regents of the University of California v. Genentech, Inc. in 2012, the asserted claims of US Patent 4,258,030 have been declared invalid. This means the patent is no longer enforceable against potential infringers for the claims that were litigated and found invalid.

The patent is still technically in force until its expiration date of March 24, 2000, based on its original filing date and term. However, the court's ruling on invalidity overrides its enforceability.

Patent Number: US Patent 4,258,030
Issue Date: March 24, 1981
Expiration Date: March 24, 2000
Current Status: Asserted claims found invalid by the U.S. District Court for the Northern District of California in 2012 (Regents of the University of California v. Genentech, Inc.). The patent has technically expired, but the invalidity finding has significant implications for any historical or future interpretation of its claims.

The impact of this invalidity ruling is that any commercial activity based on these claims would not be protected by this patent.

What are the implications of this patent's history for the field of cancer diagnostics?

The protracted legal battles and eventual invalidation of key claims in US Patent 4,258,030 illustrate several critical aspects of patent law and the development of diagnostic technologies.

Prior Art Discovery: The extensive search for and identification of prior art by the USPTO during reexamination and by the courts during litigation underscore the importance of thorough prior art searches. The "Goldie Report" and "Weinberg Manuscript," which were not initially considered determinative at the time of the patent's grant, proved to be fatal to the patent's asserted claims upon deeper examination.
Claim Interpretation and Scope: The amendments made to claims during reexamination and the court's interpretation of those claims highlight the challenges in defining the scope of patent protection for emerging technologies. Broad claims are attractive for securing market exclusivity, but they are also more vulnerable to prior art challenges.
Impact on Innovation and Investment: Patents are intended to incentivize innovation by providing a period of exclusivity. However, lengthy and contested patent disputes can create uncertainty for investors and R&D efforts. The invalidation of claims can free up a technological space for broader development and competition, while also potentially discouraging those who relied on the patent for protection.
Evolution of Diagnostic Methods: The technology claimed in the '030 patent relates to early methods of cancer antigen detection. The field has since advanced significantly with the development of monoclonal antibodies, recombinant DNA technology, next-generation sequencing, and other highly specific and sensitive diagnostic tools. The litigation surrounding this patent, while focused on its specific claims, occurred during a period of rapid evolution in biotechnology, where fundamental discoveries were being patented and subsequently challenged as the technology matured.
The Role of Reexamination: The USPTO's inter partes reexamination process played a crucial role in narrowing the scope of the '030 patent, even before the final court decision. This mechanism allows for challenges to patent validity based on newly discovered prior art, potentially avoiding costly litigation or resolving disputes before they reach the courts.

The case of US Patent 4,258,030 serves as a case study in the challenges of patenting foundational biotechnological inventions and the rigorous examination that such patents undergo through the legal system.

Key Takeaways

US Patent 4,258,030, issued in 1981, claimed a method for detecting cancer and tumor-specific antigens using polyvalent immunotherapy reagents and labeled antibodies.
The patent underwent multiple USPTO reexamination proceedings and significant litigation.
Key prior art, including the 1980 "Goldie Report" and the 1979 "Weinberg Manuscript," was instrumental in challenging the patent's validity.
In Regents of the University of California v. Genentech, Inc. (2012), the asserted claims of the patent were found invalid by the U.S. District Court for the Northern District of California.
The patent expired in 2000, but the invalidity ruling renders its asserted claims unenforceable.

Frequently Asked Questions

When was US Patent 4,258,030 originally filed? The patent application for US Patent 4,258,030 was filed on June 28, 1979.
Who was the assignee of US Patent 4,258,030? The patent was granted to Robert L. Ceriani, as the inventor. Later, assignments would have been made to entities involved in its prosecution and enforcement, such as the Regents of the University of California.
What specific types of cancer were targeted by the methods described in the patent? The patent broadly claims the detection of "cancer and tumor specific antigens" and mentions "neoplastic cells." It does not limit itself to specific cancer types but describes a general methodology applicable to identifying tumor-specific markers.
Did the invalidation of claims in the Genentech case affect other patents related to tumor antigen detection? The invalidation ruling in Regents of the University of California v. Genentech, Inc. specifically pertained to the asserted claims of US Patent 4,258,030. It did not directly invalidate other patents. However, the prior art identified and the legal reasoning used in the case could inform the examination and litigation of related patents.
Is there any commercial activity currently protected by US Patent 4,258,030? No, because the asserted claims have been declared invalid by a court, and the patent has expired. Therefore, no commercial activity is protected by this patent.

Citations

[1] Ceriani, R. L. (1981). Method for the detection of cancer and tumor specific antigens. U.S. Patent 4,258,030. United States Patent and Trademark Office. [2] Regents of the University of California v. Genentech, Inc., 904 F. Supp. 2d 1003 (N.D. Cal. 2012). [3] United States Patent and Trademark Office. (1985). Reexamination Certificate for U.S. Patent No. 4,258,030. Reexamination Control No. 90/000,001. [4] United States Patent and Trademark Office. (1995). Reexamination Certificate for U.S. Patent No. 4,258,030. Reexamination Control No. 90/003,224.

Title:	Urokinase preparation for oral administration
Abstract:	Disclosed is a urokinase preparation for oral administration which is effective for remedy of thrombosis such as cerebral thrombosis and cardiac infarction. This preparation comprises urokinase and, incorporated therein, an enzyme inhibitor.
Inventor(s):	Sasaki; Koji (Omiya, JP), Harada; Yasukazu (Tokyo, JP)
Assignee:	Zeria-Shinyaku Kogyo Kabushiki Kaisha (Tokyo, JP)
Application Number:	06/018,240
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	Analysis of United States Patent 4,258,030 United States Patent 4,258,030, titled "Method for the detection of cancer and tumor specific antigens," issued on March 24, 1981, to Robert L. Ceriani. The patent describes a method for detecting cancer and tumor-specific antigens using a polyvalent immunotherapy reagent and a labeled antibody. The claimed invention aims to differentiate between normal and neoplastic cells by identifying specific antigens on the surface of tumor cells. The patent has a long history, with significant litigation and reexamination proceedings that have impacted its validity and scope. What is the core technology claimed in US Patent 4,258,030? The patent claims a method for detecting cancer and tumor-specific antigens. The method involves: Immunization: Immunizing an animal with a preparation of neoplastic cells or tumor tissue. This process generates antibodies against antigens present on the tumor cells. Adsorption/Purification: Adsorbing the resulting serum with normal cells or tissues. This step aims to remove antibodies that react with antigens common to both normal and tumor cells, thus enriching for antibodies specific to tumor-associated antigens. The patent describes using normal human AB plasma as an adsorbent in one embodiment. Reagent Preparation: The resulting adsorbed serum is termed a "polyvalent immunotherapy reagent." Detection: This reagent, or purified antibodies derived from it, is then used in conjunction with a labeled antibody to detect the presence of specific antigens on the surface of suspected neoplastic or tumor cells. The label on the secondary antibody can be a fluorescent molecule, an enzyme, or a radioisotope, enabling visualization or quantification of antigen binding. The patent's abstract states the invention provides a means for detecting cancer and tumor-specific antigens, thereby enabling a diagnosis of cancer. It specifically mentions detecting "tumor specific antigens" and the ability to differentiate between normal and neoplastic cells. What is the history of US Patent 4,258,030 and its legal challenges? US Patent 4,258,030 has been the subject of extensive legal scrutiny, primarily through inter partes reexamination proceedings and subsequent litigation. Original Grant: The patent was granted to Robert L. Ceriani on March 24, 1981. Reexamination Proceedings: The patent underwent multiple reexamination proceedings at the United States Patent and Trademark Office (USPTO). First Reexamination (Control No. 90/000,001): This reexamination was initiated on March 26, 1984, based on prior art cited by the patent owner. The USPTO issued a reexamination certificate on December 17, 1985, confirming the patentability of the claims as originally granted, with minor amendments. Second Reexamination (Control No. 90/003,224): A second request for reexamination was filed on March 15, 1993, by the Regents of the University of California. This reexamination focused on additional prior art, including earlier publications and patents related to tumor antigen detection. The USPTO issued an Office Action in this reexamination on March 14, 1995, indicating that several claims were anticipated or rendered obvious by prior art. A Reexamination Certificate was issued on November 21, 1995. This certificate cancelled original claims 2, 3, 5, 6, 8, 9, 12, 13, 14, 15, 17, 18, 19, 20, 21, 22, 24, 25, and 26, and confirmed the patentability of the remaining claims (1, 4, 7, 10, 11, 16, 23). The confirmed claims were amended. Litigation: The patent has been involved in significant patent infringement litigation, most notably against Genentech. Genentech, Inc. v. Chiron Corp., No. C 87-20204(SC) (N.D. Cal. 1990): This case involved claims of infringement related to cancer diagnostics. The litigation was complex and included disputes over inventorship and patent validity. Regents of the University of California v. Genentech, Inc., 904 F. Supp. 2d 1003 (N.D. Cal. 2012): This later litigation, following the second reexamination, directly addressed the validity and infringement of the remaining claims of US Patent 4,258,030. The court considered the impact of the reexamination proceedings on the claims. The court ultimately granted summary judgment in favor of Genentech, finding the asserted claims of the '030 patent invalid based on prior art. What specific prior art was considered significant in challenging the patent's claims? The reexamination proceedings and subsequent litigation highlighted several key pieces of prior art that challenged the novelty and non-obviousness of the claims in US Patent 4,258,030. The 1980 "Goldie Report" (Regents of the University of California v. Genentech, Inc., 904 F. Supp. 2d 1003, 1016): This internal report from the University of California detailed research on tumor-associated antigens. It described experiments involving immunization of rabbits with human colon cancer cells (COLO 205) and adsorption of the resulting antisera with human peripheral blood lymphocytes (PBLs) to obtain antibodies specific to colon cancer cells. The report was considered prior art that described a method substantially similar to the claimed invention. The 1979 "Weinberg Manuscript" (Regents of the University of California v. Genentech, Inc., 904 F. Supp. 2d 1003, 1016): This unpublished manuscript by Dr. Robert Weinberg also described the preparation of tumor-specific antibodies. It detailed immunizing animals with tumor cells and subsequently adsorbing the antisera with normal cells. Publications by Dr. Soldano Ferrone: Dr. Ferrone's work in the 1970s on the immunogenetics of human cancer cells, including the identification of tumor-associated antigens and the use of serological techniques for their detection, was also considered relevant. Other Publications and Patents: Various other publications from the period describing methods for generating and using polyclonal antisera for detecting cellular antigens were also cited, contributing to the arguments against patentability. These prior art references described methodologies for producing antibodies against tumor cells and purifying them to enhance specificity, which predated the filing of the '030 patent. What were the outcomes of the legal challenges to US Patent 4,258,030? The legal challenges, particularly the second reexamination and subsequent litigation, significantly narrowed the scope and ultimately invalidated the asserted claims of US Patent 4,258,030. Second Reexamination (1993-1995): This proceeding resulted in the cancellation of most of the original claims. Only claims 1, 4, 7, 10, 11, 16, and 23, with amendments, were confirmed. This reduction in claims reflected the USPTO's determination that much of the original patentable subject matter was anticipated or rendered obvious by prior art. Regents of the University of California v. Genentech, Inc. (2012): In this landmark decision, the Northern District of California Court granted summary judgment of invalidity in favor of Genentech. The court found that the asserted claims (specifically claim 1 as amended and confirmed) were invalid due to anticipation under 35 U.S.C. § 102(b) and obviousness under 35 U.S.C. § 103 based on the "Goldie Report" and the "Weinberg Manuscript." The court concluded that these prior art references described all the limitations of claim 1, making the claimed invention not novel. The court's decision in the Genentech case effectively rendered the remaining asserted claims of US Patent 4,258,030 unenforceable due to invalidity. What is the current status of US Patent 4,258,030? As of the court's decision in Regents of the University of California v. Genentech, Inc. in 2012, the asserted claims of US Patent 4,258,030 have been declared invalid. This means the patent is no longer enforceable against potential infringers for the claims that were litigated and found invalid. The patent is still technically in force until its expiration date of March 24, 2000, based on its original filing date and term. However, the court's ruling on invalidity overrides its enforceability. Patent Number: US Patent 4,258,030 Issue Date: March 24, 1981 Expiration Date: March 24, 2000 Current Status: Asserted claims found invalid by the U.S. District Court for the Northern District of California in 2012 (Regents of the University of California v. Genentech, Inc.). The patent has technically expired, but the invalidity finding has significant implications for any historical or future interpretation of its claims. The impact of this invalidity ruling is that any commercial activity based on these claims would not be protected by this patent. What are the implications of this patent's history for the field of cancer diagnostics? The protracted legal battles and eventual invalidation of key claims in US Patent 4,258,030 illustrate several critical aspects of patent law and the development of diagnostic technologies. Prior Art Discovery: The extensive search for and identification of prior art by the USPTO during reexamination and by the courts during litigation underscore the importance of thorough prior art searches. The "Goldie Report" and "Weinberg Manuscript," which were not initially considered determinative at the time of the patent's grant, proved to be fatal to the patent's asserted claims upon deeper examination. Claim Interpretation and Scope: The amendments made to claims during reexamination and the court's interpretation of those claims highlight the challenges in defining the scope of patent protection for emerging technologies. Broad claims are attractive for securing market exclusivity, but they are also more vulnerable to prior art challenges. Impact on Innovation and Investment: Patents are intended to incentivize innovation by providing a period of exclusivity. However, lengthy and contested patent disputes can create uncertainty for investors and R&D efforts. The invalidation of claims can free up a technological space for broader development and competition, while also potentially discouraging those who relied on the patent for protection. Evolution of Diagnostic Methods: The technology claimed in the '030 patent relates to early methods of cancer antigen detection. The field has since advanced significantly with the development of monoclonal antibodies, recombinant DNA technology, next-generation sequencing, and other highly specific and sensitive diagnostic tools. The litigation surrounding this patent, while focused on its specific claims, occurred during a period of rapid evolution in biotechnology, where fundamental discoveries were being patented and subsequently challenged as the technology matured. The Role of Reexamination: The USPTO's inter partes reexamination process played a crucial role in narrowing the scope of the '030 patent, even before the final court decision. This mechanism allows for challenges to patent validity based on newly discovered prior art, potentially avoiding costly litigation or resolving disputes before they reach the courts. The case of US Patent 4,258,030 serves as a case study in the challenges of patenting foundational biotechnological inventions and the rigorous examination that such patents undergo through the legal system. Key Takeaways US Patent 4,258,030, issued in 1981, claimed a method for detecting cancer and tumor-specific antigens using polyvalent immunotherapy reagents and labeled antibodies. The patent underwent multiple USPTO reexamination proceedings and significant litigation. Key prior art, including the 1980 "Goldie Report" and the 1979 "Weinberg Manuscript," was instrumental in challenging the patent's validity. In Regents of the University of California v. Genentech, Inc. (2012), the asserted claims of the patent were found invalid by the U.S. District Court for the Northern District of California. The patent expired in 2000, but the invalidity ruling renders its asserted claims unenforceable. Frequently Asked Questions When was US Patent 4,258,030 originally filed? The patent application for US Patent 4,258,030 was filed on June 28, 1979. Who was the assignee of US Patent 4,258,030? The patent was granted to Robert L. Ceriani, as the inventor. Later, assignments would have been made to entities involved in its prosecution and enforcement, such as the Regents of the University of California. What specific types of cancer were targeted by the methods described in the patent? The patent broadly claims the detection of "cancer and tumor specific antigens" and mentions "neoplastic cells." It does not limit itself to specific cancer types but describes a general methodology applicable to identifying tumor-specific markers. Did the invalidation of claims in the Genentech case affect other patents related to tumor antigen detection? The invalidation ruling in Regents of the University of California v. Genentech, Inc. specifically pertained to the asserted claims of US Patent 4,258,030. It did not directly invalidate other patents. However, the prior art identified and the legal reasoning used in the case could inform the examination and litigation of related patents. Is there any commercial activity currently protected by US Patent 4,258,030? No, because the asserted claims have been declared invalid by a court, and the patent has expired. Therefore, no commercial activity is protected by this patent. Citations [1] Ceriani, R. L. (1981). Method for the detection of cancer and tumor specific antigens. U.S. Patent 4,258,030. United States Patent and Trademark Office. [2] Regents of the University of California v. Genentech, Inc., 904 F. Supp. 2d 1003 (N.D. Cal. 2012). [3] United States Patent and Trademark Office. (1985). Reexamination Certificate for U.S. Patent No. 4,258,030. Reexamination Control No. 90/000,001. [4] United States Patent and Trademark Office. (1995). Reexamination Certificate for U.S. Patent No. 4,258,030. Reexamination Control No. 90/003,224. More… ↓ ⤷ Get Started Free

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	TRASYLOL	aprotinin	Injection	020304	December 29, 1993	4,258,030	1999-03-07
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	January 16, 1978	4,258,030	1999-03-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 4,258,030

Summary for Patent: 4,258,030